1 completed, 1 recruiting. 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Astrocytoma, IDH-Mutant: new trials by email Literature Review of Astrocytoma, IDH-Mutant trials Research Report on Astrocytoma, IDH-Mutant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy Assessment, Questionnaire Administration, Telemedicine Visit - Astrocytoma, IDH-Mutant, Glioblastoma | Phase 4 | Completed | Mayo Clinic | 30 | 2024-10-07 | 2026-04-29 |
| Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma Eflornithine (Dose Level 1), Eflornithine (Dose Level 2), Eflornithine (Dose Level -1) - Glioblastoma, IDH-wildtype, Glioblastoma | Phase 1 | Recruiting | Orbus Therapeutics, Inc. | 66 | 2023-07-24 | 2025-06-25 |
Astrocytoma (2) · Glioblastoma (2) · Glioma (1) · Oligodendroglioma (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Nerve Tissue (2) · Neoplasms, Neuroepithelial (2) · Neuroectodermal Tumors (2) · Glioma (1)
Temozolomide (2) · Eflornithine (1) · Observational Studies as Topic (1) · Outcome Assessment, Health Care (1) · Restraint, Physical (1)
Mayo Clinic (1) · Orbus Therapeutics, Inc. (1)
United States (2)
Howard Colman, MD, PhD (1) · Tufia C. Haddad, MD (1) · Ugur T. Sener, MD (1)